Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard

NEW YORK, April 28, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Actavis Plc (NYSE: ACT) and C.R. Bard Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1687-100free.

Biogen Idec Inc. Analyst Notes
On April 24, 2014, Biogen Idec Inc. (Biogen) and Quintiles (Quintiles) issued a joint press release stating that they have entered into a five-year strategic agreement designed to leverage the expertise and experience from both organizations to optimize Biogen Idec's clinical development processes. According to the Company, the collaboration is designed to improve clinical trial efficiency, with a focus on transparency, quality, innovation and operational excellence. Under the agreement, a team from Quintiles will work with Biogen on the design, planning and execution of Biogen's phase II-IV studies and select phase I studies. Alfred Sandrock, M.D., Ph.D., Group Senior Vice President, Development Sciences and Chief Medical Officer, Biogen, said, "What attracted us to Quintiles was their depth and breadth of experience, which we believe will enhance the design, planning and operational elements of our clinical programs." The full analyst notes on Biogen are available to download free of charge at:

http://www.analystsreview.com/1687-BIIB-28Apr2014.pdf

Bristol-Myers Squibb Co. Analyst Notes
On April 22, 2014, Bristol-Myers Squibb Co. (Bristol-Myers) and Samsung BioLogics (Samsung) jointly announced that they will increase the scope of their existing manufacturing agreement under which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Bristol-Myers and Samsung signed their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance. The financial terms of the agreement were not disclosed. Lou Schmukler, President, Global Manufacturing & Supply, Bristol-Myers, commented, "The expanded relationship with Samsung will increase our biologics manufacturing capability and give us the flexibility to respond to increased demand in order to meet the global needs of patients." The full analyst notes on Bristol-Myers are available to download free of charge at:

http://www.analystsreview.com/1687-BMY-28Apr2014.pdf

AbbVie Inc. Analyst Notes
On April 23, 2014, AbbVie Inc. (AbbVie) announced that the Company will present the data related to evaluation of a number of investigational compounds in the Company's oncology pipeline at the upcoming 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from May 30, 2014 to June 3, 2014 in Chicago. AbbVie informed that it will present the data that evaluates potential treatments for some of the most widespread and difficult-to-treat cancers. Data accepted for presentation include the results from three clinical trials evaluating the safety and efficacy of ABT-199/GDC-0199, a B-cell lymphoma-2 (BCL-2) selective inhibitor, in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL) and the results of a Phase I clinical trial of ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, for the treatment of glioblastoma multiforme. The full analyst notes on AbbVie are available to download free of charge at:

http://www.analystsreview.com/1687-ABBV-28Apr2014.pdf

Actavis Plc Analyst Notes
On April 21, 2014, Actavis Plc (Actavis) announced that G. Frederick Wilkinson, President, Actavis Global R&D, wishes to leave the Company with effect from April 25, 2014. The Company informed that Wilkinson has accepted the position of President and CEO at Impax Laboratories Inc. Paul M. Bisaro, Chairman and CEO of Actavis, said, "Over the past five years, Fred has played an essential role in our evolution from a primarily generics company to a leading specialty pharmaceutical company. He was instrumental in the successful launch of Rapaflo® and Gelnique®, revitalized the brand oral contraceptive category with the innovative launch of Generess® Fe, and has broadly expanded the nascent brand development pipeline he inherited in 2009 both organically and through M&A activities." Following Wilkinson's exit, the Actavis Global R&D will report to Robert Stewart, President, Actavis Global Operations. The full analyst notes on Actavis are available to download free of charge at:

http://www.analystsreview.com/1687-ACT-28Apr2014.pdf

C.R. Bard Inc. Analyst Notes
On April 23, 2014, C.R. Bard Inc. (Bard) announced that the Company will present at the upcoming Deutsche Bank Healthcare Conference on May 7, 2014 in Boston, Massachusetts. The Company informed that its Chairman and CEO, Timothy M. Ring will discuss about the Company in a presentation scheduled at 1:30 p.m. EDT. The full analyst notes on Bard are available to download free of charge at:

http://www.analystsreview.com/1687-BCR-28Apr2014.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review